Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

/PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug...

Related Keywords

Australia ,Japan ,Canada ,United Kingdom ,Brussels ,Bruxelles Capitale ,Belgium ,Switzerland ,Great Britain ,Nicole Herga ,Eimear Obrien ,Iris Loew Friedrich ,Antje Witte ,Laurent Schots ,J Clin Pharmacol ,Brand Communications ,Twitter ,Immunology Communications ,Drug Administration ,European Union Eu Economic Area ,International Federation Of Psoriasis Associations ,Corporate Communications ,National Psoriasis Foundation ,Source Ucb Inc ,Regulated Information ,Inside Information ,Biologics License Application ,Prescription Drug User Fee Action ,Chief Medical Officer ,Executive Vice President ,European Union ,European Economic Area ,Euronext Brussels ,Supply Chain ,Drug Inspections ,Product Characteristics ,Dermatol Ther ,Psoriatic Arthritis ,Population Based Multinational Assessment ,Ucb ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,